Matches in SemOpenAlex for { <https://semopenalex.org/work/W2014372264> ?p ?o ?g. }
Showing items 1 to 91 of
91
with 100 items per page.
- W2014372264 abstract "Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CABackground:Activation of the extrinsic apoptosis pathway in tumor cells through agonistic death receptor 5 (DR5) antibodies has been evaluated in the clinic with limited success so far. In this context, several reports show that DR5 activation is strongly dependent on receptor hyperclustering on the cell surface. Therefore a therapeutic principle that induces DR5 hyperclustering specifically at the tumor site may provide superior efficacy, potency and safety compared to conventional DR5 agonistic antibodies. Fibroblast activation protein (FAP) is a marker for activated fibroblasts and abundantly expressed in cancer associated fibroblasts of various epithelial tumor indications and as a tumor antigen on tumors of mesenchymal origin. Due to its relative absence from normal tissues, FAP can be used as a tumor targeting antigen. Here, we are using the broad expression of FAP in tumor stroma for crosslinking of DR5 by a bispecific antibody.Aim:In order to achieve superior tumor targeting and tumor located DR5 hyperclustering we have generated a bispecific antibody, RG7386, comprised of an agonistic DR5 binder and a FAP targeting moiety.Results:RG7386 shows potent and selective binding to FAP and DR5 and can simultaneously bind to both targets. In in vitro co-culture assays, using human DLD-1 colon cancer cells and FAP expressing fibroblasts, RG7386 induces potent, FAP dependent DR5 hyperclustering and apoptosis induction in DR5 positive tumor cells (IC50: 0.05 nM). In preclinical in vivo models with co-injection of DLD-1 tumor cells and fibroblasts as well as patient-derived colorectal cancer models, RG7386 shows FAP dependent efficacy and apoptosis induction superior to conventional DR5 antibodies. Furthermore the superior induction of apoptosis could be confirmed by in vivo and ex vivo analysis of cleaved Caspase-3 with imaging, Luminex and histopathology.Conclusion:RG7386 is a promising novel therapeutic entity for the treatment of solid tumors with FAP positive tumor stroma inducing DR5 activation by FAP dependent DR5 hypercrosslinking which results in potent anti-tumor activity.Citation Format: Katharina Wartha, Barbara Weiser, Thomas Friess, Meher Majety, Valeria Runza, Frank Herting, Thomas Weber, Werner Scheuer, Suzana Vega Harring, Hadassah Sade, Huifeng Niu, Peter Bruenker. A novel bispecific Fap-Dr5 antibody inducing potent and tumor-specific death receptor 5 (Dr5) activation by fibroblast activation protein (Fap)-dependent crosslinking. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 4573. doi:10.1158/1538-7445.AM2014-4573" @default.
- W2014372264 created "2016-06-24" @default.
- W2014372264 creator A5004333239 @default.
- W2014372264 creator A5006765090 @default.
- W2014372264 creator A5007078235 @default.
- W2014372264 creator A5014716846 @default.
- W2014372264 creator A5015064646 @default.
- W2014372264 creator A5015827960 @default.
- W2014372264 creator A5025250615 @default.
- W2014372264 creator A5045802432 @default.
- W2014372264 creator A5058508912 @default.
- W2014372264 creator A5073223225 @default.
- W2014372264 creator A5073502196 @default.
- W2014372264 creator A5090911148 @default.
- W2014372264 date "2014-09-30" @default.
- W2014372264 modified "2023-09-25" @default.
- W2014372264 title "Abstract 4573: A novel bispecific Fap-Dr5 antibody inducing potent and tumor-specific death receptor 5 (Dr5) activation by fibroblast activation protein (Fap)-dependent crosslinking" @default.
- W2014372264 doi "https://doi.org/10.1158/1538-7445.am2014-4573" @default.
- W2014372264 hasPublicationYear "2014" @default.
- W2014372264 type Work @default.
- W2014372264 sameAs 2014372264 @default.
- W2014372264 citedByCount "1" @default.
- W2014372264 countsByYear W20143722642016 @default.
- W2014372264 crossrefType "proceedings-article" @default.
- W2014372264 hasAuthorship W2014372264A5004333239 @default.
- W2014372264 hasAuthorship W2014372264A5006765090 @default.
- W2014372264 hasAuthorship W2014372264A5007078235 @default.
- W2014372264 hasAuthorship W2014372264A5014716846 @default.
- W2014372264 hasAuthorship W2014372264A5015064646 @default.
- W2014372264 hasAuthorship W2014372264A5015827960 @default.
- W2014372264 hasAuthorship W2014372264A5025250615 @default.
- W2014372264 hasAuthorship W2014372264A5045802432 @default.
- W2014372264 hasAuthorship W2014372264A5058508912 @default.
- W2014372264 hasAuthorship W2014372264A5073223225 @default.
- W2014372264 hasAuthorship W2014372264A5073502196 @default.
- W2014372264 hasAuthorship W2014372264A5090911148 @default.
- W2014372264 hasConcept C111798993 @default.
- W2014372264 hasConcept C121608353 @default.
- W2014372264 hasConcept C126322002 @default.
- W2014372264 hasConcept C147483822 @default.
- W2014372264 hasConcept C153911025 @default.
- W2014372264 hasConcept C159654299 @default.
- W2014372264 hasConcept C170493617 @default.
- W2014372264 hasConcept C185592680 @default.
- W2014372264 hasConcept C190283241 @default.
- W2014372264 hasConcept C203014093 @default.
- W2014372264 hasConcept C502942594 @default.
- W2014372264 hasConcept C55493867 @default.
- W2014372264 hasConcept C71924100 @default.
- W2014372264 hasConcept C86803240 @default.
- W2014372264 hasConceptScore W2014372264C111798993 @default.
- W2014372264 hasConceptScore W2014372264C121608353 @default.
- W2014372264 hasConceptScore W2014372264C126322002 @default.
- W2014372264 hasConceptScore W2014372264C147483822 @default.
- W2014372264 hasConceptScore W2014372264C153911025 @default.
- W2014372264 hasConceptScore W2014372264C159654299 @default.
- W2014372264 hasConceptScore W2014372264C170493617 @default.
- W2014372264 hasConceptScore W2014372264C185592680 @default.
- W2014372264 hasConceptScore W2014372264C190283241 @default.
- W2014372264 hasConceptScore W2014372264C203014093 @default.
- W2014372264 hasConceptScore W2014372264C502942594 @default.
- W2014372264 hasConceptScore W2014372264C55493867 @default.
- W2014372264 hasConceptScore W2014372264C71924100 @default.
- W2014372264 hasConceptScore W2014372264C86803240 @default.
- W2014372264 hasLocation W20143722641 @default.
- W2014372264 hasOpenAccess W2014372264 @default.
- W2014372264 hasPrimaryLocation W20143722641 @default.
- W2014372264 hasRelatedWork W1560585642 @default.
- W2014372264 hasRelatedWork W1567564751 @default.
- W2014372264 hasRelatedWork W1595206199 @default.
- W2014372264 hasRelatedWork W1979185488 @default.
- W2014372264 hasRelatedWork W1986165319 @default.
- W2014372264 hasRelatedWork W2013289064 @default.
- W2014372264 hasRelatedWork W2041652007 @default.
- W2014372264 hasRelatedWork W2048675139 @default.
- W2014372264 hasRelatedWork W2080761304 @default.
- W2014372264 hasRelatedWork W2114636499 @default.
- W2014372264 hasRelatedWork W2130305891 @default.
- W2014372264 hasRelatedWork W2739623064 @default.
- W2014372264 hasRelatedWork W2741934102 @default.
- W2014372264 hasRelatedWork W2752971182 @default.
- W2014372264 hasRelatedWork W2885742679 @default.
- W2014372264 hasRelatedWork W2886168888 @default.
- W2014372264 hasRelatedWork W2886505143 @default.
- W2014372264 hasRelatedWork W2887637168 @default.
- W2014372264 hasRelatedWork W2914460377 @default.
- W2014372264 hasRelatedWork W2915018676 @default.
- W2014372264 isParatext "false" @default.
- W2014372264 isRetracted "false" @default.
- W2014372264 magId "2014372264" @default.
- W2014372264 workType "article" @default.